SCHEMBL1665523

SCHEMBL1665523

COC(=O)c1ccnc2nc(C)n(Cc3ccc(OC)cc3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 3/20 0.46
GLA P06280 2/20 0.46
HPGD P15428 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
HSD17B10 Q99714 2/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
DCTPP1 Q9H773 3/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
PTGS2 P35354 1/20 0.41
GSK3B P49841 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057148 0.90 FABP4 (0.49) KDM4EALDH1A1PTGDR2DCTPP1LMNA
SCHEMBL5052648 0.80 HSP90B1 (0.47) KDM4EHTT
SCHEMBL7503360 0.73 DRD2 (0.54) GAADCTPP1TP53
SCHEMBL2749169 0.70 DCTPP1 (0.60) KDM4EALDH1A1GAAHPGDDCTPP1
SCHEMBL24476642 0.69 DCTPP1 (0.52) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL19987318 0.69 KDM4E (0.68) KDM4EGAADCTPP1MAPT
SCHEMBL1667334 0.69 SMN1; SMN2 (0.47) KDM4EALDH1A1GAALMNAHTT
SCHEMBL28320349 0.68 PTGS2 (0.46) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL3675331 0.68 GRK6 (0.44) KDM4EALDH1A1NPSR1MAPK1HTT
SCHEMBL23206336 0.67 SMN1; SMN2 (0.52) KDM4EGAALMNAMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
EP-1891042-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA SA (BE) 2013-10-02 EP disclosed
US-8518943-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-08-27 US disclosed
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-23 US disclosed
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-02 US disclosed
EP-2308867-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 EP disclosed
EP-2308870-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 KDM4E 1184/4885ALDH1A1 560/4885GAA 138/4885
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 KDM4E 1184/4885ALDH1A1 560/4885GAA 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.